In this episode of the Queens of Quality podcast, we explore the importance of discussing failure alongside success in the pharmaceutical and biotech industries. With only a small percentage of drugs making it to clinical testing, failure is an integral part of the industry. We discuss the lengthy process of bringing a product to market, the challenges faced, and the significance of collaboration between academia and the industry. Join us as we delve into the complexities of drug development and the lessons learned from failures. Don't forget to subscribe, like, review, and share the podcast to help us continue the conversation.
Tune in!
During this episode, you will learn about;
0:00:32 The Queens of Quality discuss the topic of failure
0:02:05 From Bench to Bedside: Pharma Industry's Journey
0:05:14 The Challenge of Identifying the Right Target
0:07:57 Ensuring Support and Documentation for Clinical Phases
0:10:10 Phase One Trials: High Failure Rate and Cost Implications
0:12:05 Multiple Development Paths and the Importance of Phase Two
0:14:22 Phase Three Trials: Expanding Patient Population and Clinical Programs
0:15:52 The Final Stretch: Phase Three Programs
0:16:19 The Reality: Fast-paced and Not Funny
0:18:23 Long Timelines and Challenges in Clinical Trials
0:20:35 Study Drug Adherence: A Critical Factor in Audits
0:21:15 High Adherence Rate in Children's Oncology Study
0:23:25 The Importance of Reinvestment and Balancing Product Pipeline
0:25:31 Collaboration between academia and industry in pharmaceutical innovation
0:28:02 Progress and success in the pharma and biotech industry
0:31:16 Wrapping up the Queens of Quality Podcast
Love the show? Subscribe, Rate, Review, Like, and Share!
Let’s Connect!